About Flavocure Biotech
Flavocure Biotech is a private company based in Baltimore, Maryland. It has reported $1,340,000 raised in two offerings on Form D since January 2023. Its chief executive is Ngeh Toyang.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Feb 5, 2025 | Feb 21, 2025 | $215,000of $2.0M target | 3 | $71,667 | EquityRule 506(b) | Form D ↗ |
| Dec 20, 2022 | Jan 4, 2023 | $1,125,000of $1.2M target | 3 | $375K | Equity, Shares and WarrantsRule 506(b) | Form D ↗ |
| Total, two offerings | $1,340,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Flavocure Biotech's Form D filed Feb 21, 2025.
Earlier filings also listed Thomas Lang (executive officer, last listed Jan 2023), Theresia Toyeng (promoter, last listed Jan 2023), Swen Simms (environmental health foundation, last listed Jan 2023), Saurabh Sewak (promoter, last listed Jan 2023), Eric Chapman (chapman group, last listed Jan 2023), David Traylor (golden eagle partners, last listed Jan 2023), David Brooks (executive officer, last listed Jan 2023) and Anthony Deasey (promoter, last listed Jan 2023).